Roth Capital Starts PTC Therapeutics (PTCT) at Buy
Tweet
Share
E-mailGet Alerts PTCT Hot Sheet
Price: $64.78 -0.28%
Rating Summary:
18 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 35
Rating Summary:
18 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 35
Join SI Premium – FREE
Roth Capital initiated coverage on PTC Therapeutics (NASDAQ: PTCT) with a Buy rating and a price target of $34.00.
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $27.26 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Canaccord Starts First Tracks Biotherapeutics (TRAX) at Buy
- Goldman Sachs Resumes Enbridge (ENB) at Neutral
- Stifel Starts Immunome Inc. (IMNM) at Hold
Create E-mail Alert Related Categories
New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
